Free Trial

Passage Bio (PASG) Competitors

Passage Bio logo
$0.43 -0.02 (-5.39%)
As of 02:00 PM Eastern

PASG vs. PROC, SGMT, IOBT, CABA, IMAB, SAVA, VXRT, CRDL, KRRO, and VIRI

Should you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Procaps Group (PROC), Sagimet Biosciences (SGMT), IO Biotech (IOBT), Cabaletta Bio (CABA), I-Mab (IMAB), Cassava Sciences (SAVA), Vaxart (VXRT), Cardiol Therapeutics (CRDL), Korro Bio (KRRO), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical products" industry.

Passage Bio vs. Its Competitors

Procaps Group (NASDAQ:PROC) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability.

Procaps Group's return on equity of 0.00% beat Passage Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Procaps GroupN/A N/A N/A
Passage Bio N/A -72.53%-52.10%

Passage Bio received 50 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 68.83% of users gave Passage Bio an outperform vote while only 37.50% of users gave Procaps Group an outperform vote.

CompanyUnderperformOutperform
Procaps GroupOutperform Votes
3
37.50%
Underperform Votes
5
62.50%
Passage BioOutperform Votes
53
68.83%
Underperform Votes
24
31.17%

Passage Bio has a consensus price target of $7.50, suggesting a potential upside of 1,672.63%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts clearly believe Passage Bio is more favorable than Procaps Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Procaps Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Passage Bio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Procaps Group has higher revenue and earnings than Passage Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Procaps Group$409.92M0.26$42.54MN/AN/A
Passage BioN/AN/A-$102.06M-$1.02-0.41

53.5% of Passage Bio shares are held by institutional investors. 19.9% of Procaps Group shares are held by company insiders. Comparatively, 5.0% of Passage Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Procaps Group has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500.

In the previous week, Passage Bio had 1 more articles in the media than Procaps Group. MarketBeat recorded 1 mentions for Passage Bio and 0 mentions for Procaps Group. Passage Bio's average media sentiment score of 1.87 beat Procaps Group's score of 0.00 indicating that Passage Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Procaps Group Neutral
Passage Bio Very Positive

Summary

Passage Bio beats Procaps Group on 9 of the 14 factors compared between the two stocks.

Get Passage Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PASG vs. The Competition

MetricPassage BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$26.30M$3.09B$5.59B$8.63B
Dividend YieldN/A1.57%5.28%4.18%
P/E Ratio-0.3632.9427.2120.00
Price / SalesN/A465.00411.62157.76
Price / CashN/A168.6838.2534.64
Price / Book0.213.417.114.70
Net Income-$102.06M-$72.35M$3.24B$248.05M
7 Day Performance-5.98%7.18%2.54%2.51%
1 Month Performance37.24%17.64%8.76%6.17%
1 Year Performance-58.92%-17.25%31.37%13.72%

Passage Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PASG
Passage Bio
2.9601 of 5 stars
$0.43
-5.4%
$7.50
+1,628.9%
-57.9%$26.96MN/A-0.37130Positive News
Gap Down
PROC
Procaps Group
N/A$0.95
-40.3%
N/A-62.7%$107.18M$409.92M0.004,900Gap Down
High Trading Volume
SGMT
Sagimet Biosciences
2.3745 of 5 stars
$3.49
-1.7%
$22.40
+541.8%
+24.8%$107.06M$2M-1.988News Coverage
IOBT
IO Biotech
4.0512 of 5 stars
$1.62
+14.1%
$9.33
+476.1%
+13.6%$106.73MN/A-1.1830Positive News
Short Interest ↓
Gap Up
High Trading Volume
CABA
Cabaletta Bio
2.8991 of 5 stars
$2.06
+10.2%
$20.33
+887.1%
-84.2%$104.53MN/A-0.9650Trending News
Analyst Forecast
Analyst Revision
IMAB
I-Mab
3.3577 of 5 stars
$1.28
-2.3%
$5.50
+329.7%
+33.9%$104.53M$3.27M0.00380News Coverage
Positive News
Gap Down
SAVA
Cassava Sciences
4.2777 of 5 stars
$2.13
+6.0%
$54.50
+2,458.7%
-88.9%$102.90MN/A-1.5430Positive News
VXRT
Vaxart
2.1121 of 5 stars
$0.45
+3.9%
$3.00
+566.7%
-34.5%$102.70M$47.40M-1.10120Gap Down
CRDL
Cardiol Therapeutics
2.3466 of 5 stars
$1.24
-0.8%
$8.67
+598.9%
-51.0%$102.44MN/A-3.1820Gap Up
KRRO
Korro Bio
3.5724 of 5 stars
$10.80
-5.4%
$102.43
+848.4%
-64.8%$101.42M$4.82M-1.1470Positive News
Analyst Revision
High Trading Volume
VIRI
Virios Therapeutics
N/A$5.18
-2.1%
$3.00
-42.1%
+2,104.8%$99.76MN/A-19.195

Related Companies and Tools


This page (NASDAQ:PASG) was last updated on 6/12/2025 by MarketBeat.com Staff
From Our Partners